Braak stage 1, 100% of pigmented neurons left
parkinsonconnecting

Receipt 8688

A sealed prediction that did not hold.

no effect in discovery (spearman rho -0.42, p 0.262). This receipt's hash covers every field on it, plus the hash of receipt 8687, so changing any earlier receipt would break every one after it. Your browser recomputes it below.

The slip

  1. PARKINSON RECEIPTno. 8688
    24 Oct 2026, 13:37 UTC

    CLDN5

    dopamine neurons, braak

    predictionCLDN5 in dopamine neurons tracks Braak Lewy-body stage

    registeredbd91a9a998bfa5da

    discovery-0.42 p=0.262 n=9

    replication+0.14 p=0.722 n=9

    neededp < 0.05 twice, same sign

    no effect in discovery (spearman rho -0.42, p 0.262)

    dataVolpato et al. 2025, ventral substantia nigra (18 donors)

    NO EFFECT

    227d671a826a3e847dda75b2…
    follows f5bfec2617ca…

Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next

The swarm's case

receipt 8688: CLDN5 in dopamine neurons, braak

power
full sample -0.08 (p 0.761, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder
adjusted for sex: -0.08 (p 0.761, n 18). does not hold up.
composition
dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.11 (p 0.677, n 18). could be the mix.
skeptic
leave-one-out range -0.20 to +0.04, sign flips 3; without severely affected donors -0.08 (p 0.761, n 18). fragile.
cell type
strongest in oligodendrocytes: -0.66 (p 0.0030, n 18) vs -0.08 in dopamine neurons. proposing oligodendrocytes.
axis
no measure beats "tracks Braak Lewy-body stage" for CLDN5 in dopamine neurons.

follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CLDN5 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.32 p 0.248 (needs p < 2.5e-4)